Search Results
Your search for 3 matches 15284 pages
Showing 1601 - 1650Overcoming the Challenges of Treating Adolescents and Young Adults With Cancer Living in Rural Communities
It is widely acknowledged that patients with cancer living in rural areas of the United States face limited access to medical and oncology providers, often have to travel long distances to receive care, and experience obstacles in clinical trial participation—all of which affect quality of care and ...
Comparing Two Radiation Therapy Techniques for Locally Advanced NSCLC: Focus on Toxicity
Intensity-modulated radiation therapy (IMRT) reduced the risk of toxicity to the lungs and radiation exposure to the heart vs three-dimensional conformal radiotherapy (3D-CRT) for the treatment of locally advanced non–small cell lung cancer (NSCLC), according to a planned long-term prospective...
Role of TROP-2–Directed Antibody-Drug Conjugates With Immune Checkpoint Inhibitors in Advanced NSCLC
Early-phase trials demonstrate the potential for TROP-2–directed antibody-drug conjugates to enhance the response to immune checkpoint inhibitors in patients with advanced non–small cell lung cancer (NSCLC) without actionable genomic alterations, several investigators reported at the International...
Gender Equity in Academic Hematology: Where There’s a ‘WiL,’ There’s a Way
Gender diversity, equity, and inclusion (DEI) in medicine has long been acknowledged as more than “the right thing to do,” with clear evidence of benefits in innovation, collaboration, and workplace culture.1 Yet the data continue to showcase challenges in achieving these goals despite women...
Getting a Cancer Diagnosis at Age 16 Has Taught Me to Live in the Present
I have been fascinated with death since I was 3 years old. I remember going to my great-grandfather’s funeral and asking my mother where my great-grandfather was. She said he is in heaven. I asked her if I were going to heaven, too, and she said, “Yes, but not for a long time.” Today, I don’t...
Breakthrough Prize, ‘Oscars of Science,’ Celebrates 2024 Laureates in Life Sciences
On September 14, 2023, the Breakthrough Prize Foundation announced the winners of the 2024 awards, honoring an esteemed group of the world’s researchers for their impactful scientific discoveries, including a subset responsible for substantial progress in the understanding and treatment of major...
From Humble Beginnings, Elisabete Weiderpass, MD, MSc, PhD, Distinguishes Herself as First Woman to Head the IARC
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Elisabete Weiderpass, MD, MSc, PhD, a Brazilian cancer researcher who is a naturalized Swedish and Finnish citizen. She is an expert in cancer epidemiology and cancer prevention. In...
Expert Point of View: Helena Linardou, MD, PhD
Helena Linardou, MD, PhD, Director of the 4th Department of Oncology and the Comprehensive Clinical Trials Center, Metropolitan Hospital, Athens, served as discussant of the session on antibody-drug conjugates at the 2023 World Conference on Lung Cancer. Calling antibody-drug conjugates “the next...
HERTHENA-Lung01: Antitumor Activity Shown With HER3-DXd in EGFR-Mutated NSCLC
The treatment of patients with epidermal growth factor receptor (EGFR)-mutated lung cancer that progresses on EGFR-targeted tyrosine kinase inhibitors has been challenging. In the phase II HERTHENA-Lung01 trial, the topoisomerase-1 HER3-targeting antibody-drug conjugate patritumab deruxtecan...
PSMAfore: Lutetium Lu-177 Vipivotide Tetraxetan in Metastatic Prostate Cancer
Data from the phase III PSMAfore trial were presented during a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2023 (Abstract LBA13). Results showed that the trial of lutetium Lu-177 vipivotide tetraxetan met its primary endpoint, with a clinically meaningful and ...
Nivolumab Plus Gemcitabine and Cisplatin May Improve Survival in Patients With Metastatic Urothelial Carcinoma
Researchers have found that nivolumab in combination with a chemotherapy regimen may improve the rate of survival in patients with metastatic urothelial carcinoma, according to new findings simultaneously published by van der Heijden et al in The New England Journal of Medicine and presented at the ...
Cabozantinib for Pretreated Patients With Advanced Neuroendocrine Tumors: CABINET Trial
The Alliance for Clinical Trials in Oncology announced detailed results from CABINET (Alliance A021602), a phase III pivotal trial evaluating cabozantinib compared with placebo in two cohorts of previously treated patients with neuroendocrine tumors. The data were presented by Chan et al at the...
Erdafitinib Demonstrates Improved Responses in FGFR-Altered Advanced Urothelial Carcinoma
Targeted treatment with the fibroblast growth factor receptor (FGFR) inhibitor erdafitinib improved responses and overall survival compared to standard chemotherapy for patients with advanced or metastatic urothelial carcinoma with FGFR alterations. Results from the phase III THOR trial, led by...
ESMO 2023: New Data in Skin Cancers
At the European Society for Medical Oncology (ESMO) Congress 2023, new findings are being presented in cutaneous squamous cell carcinoma, late-stage melanoma, and refractory melanoma brain metastases. Presurgical Immunotherapy in Advanced Operable Cutaneous Squamous Cell Carcinoma Patients with...
EVEREST Trial: Adjuvant Everolimus for High-Risk Clear Cell Renal Cell Carcinoma
A secondary analysis from the phase III SWOG S0931 EVEREST trial found patients with clear cell renal cell carcinoma at very high risk of recurrence after nephrectomy who received adjuvant everolimus had a statistically significant improvement in recurrence-free survival compared to patients who...
Pre- and Postsurgical Immunotherapy Improves Outcomes for Patients With Resectable Early-Stage NSCLC
Compared with neoadjuvant chemotherapy alone, adding perioperative immunotherapy—given before and after surgery—significantly improved event-free survival in patients with resectable early-stage non–small cell lung cancer (NSCLC). Results from the phase III CheckMate 77T study were presented at the ...
Tislelizumab vs Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma
In the phase III RATIONALE-301 trial reported in JAMA Oncology, Shukui Qin, MD, PhD, and colleagues found that tislelizumab was noninferior to sorafenib in terms of overall survival as first-line treatment for patients with unresectable hepatocellular carcinoma. Study Details In the open-label...
Blood-Based Testing for Multicancer Early Detection
In a prospective cohort study (PATHFINDER) reported in The Lancet, Deb Schrag, MD, MPH, FASCO, and colleagues evaluated the performance of blood-based testing for multicancer early detection in adults without signs or symptoms of cancer. As stated by the investigators, “Multicancer early detection ...
MRI Scans Could Predict Postradiation Urinary Side Effects in Patients With Prostate Cancer
Researchers have discovered that patients with longer prostatic urethras may have an increased risk of experiencing moderate and chronic urinary side effects after receiving radiation for prostate cancer, according to a recent study published by Lee et al in Academic Radiology. The new findings...
Do Low- and Moderate-Grade Adverse Events Affect Rates of Treatment Discontinuation in CLL?
In an analysis from the phase III ECOG/ACRIN E1912 trial in chronic lymphocytic leukemia (CLL) published in the Journal of Clinical Oncology, O’Connell et al found that grade 1 and 2 adverse events were significant contributors to patient-reported side-effects bother, with grade 2 events being...
Addition of Berzosertib to Topotecan in Relapsed SCLC
In a phase II trial reported in JAMA Oncology, Takahashi et al found that the addition of the ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor berzosertib to topotecan did not improve progression-free survival in patients with relapsed small cell lung cancer (SCLC). However, an overall ...
FDA Approves Neoadjuvant/Adjuvant Pembrolizumab for Resectable NSCLC
On October 16, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of single-agent pembrolizumab as postsurgical adjuvant treatment, for resectable (tumors ≥ 4 cm or node-positive)...
Breast Cancer 2022–2023 Almanac
The past year has been an exciting time for breast oncologists and patients with all stages of breast cancer, with new agents approved and long-term results from pivotal trials showing improved survival for patients with metastatic disease. Let’s take a look at some of the highlights in early-stage ...
Recent FDA Approvals in Breast Cancer
Over the past year, the U.S. Food and Drug Administration (FDA) granted approval to several novel drugs and expanded indications for older therapeutic agents used in breast cancer. Abemaciclib Plus Endocrine Therapy On March 3, 2023, the FDA expanded the indication for abemaciclib with endocrine...
Expert Point of View: Meritxell Bellet Ezquerra, MD, PhD, and Sung-Bae Kim, MD, PhD
The MONARCH 3 study’s invited discussant, Meritxell Bellet Ezquerra, MD, PhD, a senior researcher at the Vall d’Hebron Institute of Oncology in Barcelona, commented: “The second interim analysis for overall survival in MONARCH 31 indicates a positive trend, which was also observed for the subgroup...
Overall Survival in Two Monarch Trials of Abemaciclib in Advanced Breast Cancer
Overall survival results from two trials of abemaciclib in advanced breast cancer were reported at the European Society for Medical Oncology (ESMO) Congress 2022. Both MONARCH 3 and monarcHER previously met their primary endpoints of progression-free survival. The current results for overall...
Can Younger Women With Hormone Receptor–Positive Breast Cancer Safely Pause Endocrine Therapy to Pursue Pregnancy?
Preserving fertility is a driving concern for many young women with breast cancer. Many of these women have hormone receptor–positive breast cancer and are treated with adjuvant endocrine therapy for 5 to 10 years, which is known to compromise fertility. Younger women who may want to take a break...
SOFT Analysis: Breast Cancer Index May Identify Which Patients Need Ovarian Suppression
In an analysis of the SOFT trial, the Breast Cancer Index accurately identified premenopausal women with hormone receptor–positive early breast cancer who may benefit from ovarian function suppression in addition to adjuvant endocrine therapy. The findings were reported by Ruth O’Regan, MD, Chair...
Capivasertib Plus Fulvestrant Doubles Progression-Free Survival in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
The combination of capivasertib, an AKT pathway inhibitor, plus fulvestrant, an estrogen receptor antagonist, significantly improved progression-free survival compared with fulvestrant alone in patients with hormone receptor–positive, HER2-negative advanced breast cancer, according to results of...
Palbociclib/Fulvestrant Does Not Improve Progression-Free Survival After Progression on a CDK4/6 Inhibitor in Metastatic Breast Cancer
The combination of palbociclib and fulvestrant did not prolong progression-free survival compared to fulvestrant alone in patients with hormone receptor–positive/HER2-negative metastatic breast cancer who had disease progression on prior treatment with a CDK4/6 inhibitor and endocrine therapy,...
T-DXd Confirmed as Preferred Second-Line Therapy for Metastatic HER2-Positive Breast Cancer
The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) proved to be superior to the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1), significantly improving progression-free survival and overall survival, in women with unresectable or metastatic HER2-positive breast cancer as ...
EMERALD Trial: Elacestrant vs Standard Endocrine Monotherapy for Advanced Breast Cancer After CDK4/6 Inhibition
Elacestrant—an investigational oral selective estrogen receptor degrader (SERD)—achieved longer progression-free survival vs standard-of-care endocrine monotherapy as second- or third-line therapy in patients with estrogen receptor–positive, HER2-negative advanced or metastatic breast cancer in the ...
Expert Point of View: Nancy Chan, MD
Nancy Chan, MD, Director of Breast Cancer Clinical Research at NYU Langone’s Perlmutter Cancer Center, New York, commented on the monarchE analysis for The ASCO Post. She noted that the study investigated the addition of adjuvant abemaciclib (an oral CDK4/6 inhibitor) to endocrine therapy in a...
Update From monarchE: Benefit of Abemaciclib Increases Over Time in Early-Stage Breast Cancer
Results of a planned interim overall survival analysis of the phase III monarchE trial offered further support for the addition of abemaciclib to adjuvant endocrine therapy for patients with hormone receptor–positive, HER2-negative, node-positive, high-risk disease, according to Stephen R.D....
Many Survivors of Childhood Cancer Experience Lifelong Chronic Health Problems and Shorter Lifespans Than Their Healthier Peers
Each year, nearly 16,000 children between the ages of 0 and 19 years are diagnosed with cancer, and more than 85% survive for at least 5 years. Overall, this is a large increase in survivors since the mid-1970s, when the 5-year survival rate was just 58%. Today, approximately 500,000 people in the...
FDA Approves Adjuvant Nivolumab for Stage IIB/IIC Melanoma
On October 13, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo) for the adjuvant treatment of completely resected stage IIB or IIC melanoma in patients aged 12 years and older. CheckMate 76K Efficacy was evaluated in CheckMate 76K (ClinicalTrials.gov identifier NCT04099251),...
Lung ART Trial: End of the Road for Postoperative Radiotherapy?
Lung cancer is a significant global health issue, remaining the leading cause of cancer-related deaths with 2.1 million new cases and 1.8 million deaths. Complete surgical resection is the treatment of choice for operable early-stage non–small cell lung cancer (NSCLC) and resectable stage IIIA...
How War Has Disrupted the Management of Patients With Breast Cancer in Sudan
Sudan is the third-largest country in Africa, spanning 1,886,068 km2. It is situated in an area surrounded by North Africa, Sub-Saharan Africa, and the Middle East. As of 2020, Sudan had a population of approximately 43.8 million people, with a significant proportion being younger than age 15....
Expert Point of View: Michail Ignatiadis, MD, PhD and Stephen R.D. Johnston, MD, PhD
The September 2023 European Society for Medical Oncology (ESMO) Virtual Plenary presentation of the NATALEE health-related quality-of-life (QOL) findings was discussed by Michail Ignatiadis, MD, PhD, and Stephen R.D. Johnston, MD, PhD. Dr. Ignatiadis is Director of the Breast Medical Oncology...
NATALEE Trial: Quality of Life Maintained for Many Patients Treated With Ribociclib for Early-Stage Breast Cancer
An analysis of patient-reported outcomes in the adjuvant phase III NATALEE trial of ribociclib plus endocrine therapy in early-stage breast cancer showed maintenance of health-related quality of life (QOL), as determined by a number of factors. For patients receiving the inhibitor of...
Cadonilimab, an Anti–PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors
In a Chinese phase 1b/II trial (COMPASSION-03) reported in The Lancet Oncology, Gao et al found that the anti–PD-1/CTLA-4 bispecific antibody cadonilimab showed activity in previously treated patients with a range of advanced solid tumors, including advanced cervical cancer, esophageal squamous...
FDA Grants Marketing Authorization to Edison Histotripsy System for Treatment of Liver Tumors
On October 9, HistoSonics, the manufacturer of the Edison System and novel histotripsy therapy platforms, announced the marketing authorization of its platform via the U.S. Food and Drug Administration's (FDA) De Novo Classification Request process, a rigorous premarket review pathway for medical...
IVIG May Reduce Infection Risk Among Patients With Multiple Myeloma Receiving Anti-BCMA Therapy
Although the 5-year survival rate for multiple myeloma has increased over the past 2 decades—from about 35% in 2000 to approximately 62% in 2015—due to more effective therapies, the cancer remains incurable. According to the American Cancer Society, this year, nearly 36,000 individuals will be...
Adjuvant Canakinumab in Completely Resected NSCLC
In the phase III CANOPY-A trial reported in Journal of Clinical Oncology, Edward B. Garon, MD, and colleagues found that adjuvant therapy with the interleukin (IL)-1β pathway inhibitor canakinumab did not significantly improve disease-free survival vs placebo in patients with completely resected...
Guideline Update Reflects Recent Surge of New Data in Systemic Therapy for Melanoma
A guideline update on systemic treatment for melanoma offers new guidance in several areas, including the selection of front-line therapy for patients with metastatic disease with and without BRAF mutations, treatment of patients with earlier-stage disease in the adjuvant setting, and emerging...
Melphalan-Based Liver-Directed Therapy for Metastatic Uveal Melanoma
On August 14, 2023, the Hepzato Kit—melphalan for injection/hepatic delivery system—was approved as a liver-directed treatment for adults with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver.1 Patients must have either no extrahepatic disease or extrahepatic ...
Accelerated Approval Granted for Use of Elranatamab-bcmm in Relapsed or Refractory Multiple Myeloma
On August 14, 2023, the bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager elranatamab-bcmm was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of...
Expert Point of View: Gentry King, MD
Gentry King, MD, Assistant Professor in the Division of Hematology and Oncology, University of Washington, and Assistant Professor in the Clinical Research Division of Fred Hutchinson Cancer Center, Seattle, offered his thoughts on the findings of NuTide:121. “Only recently, with TOPAZ-1...
NUC-1031/Cisplatin Fails to Improve Outcomes in Advanced Biliary Tract Cancer
As a first-line treatment for advanced biliary tract cancer, an experimental formulation of gemcitabine, NUC-1031, given with cisplatin failed to improve outcomes over standard gemcitabine/cisplatin in the global phase III NuTide:121 trial.1 “NuTide:121 has not advanced the field in biliary tract...
Checkpoint Inhibitors Offer Limited Benefit in EGFR-Mutated Lung Cancer After Disease Progression
In advanced non–small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR), the role of immune checkpoint inhibitors following disease progression with tyrosine kinase inhibitors has been unclear. Several studies reported at the International Association for the Study ...
